UnknownPhase 4

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

United States10 participantsStarted 2021-08-09

Plain-language summary

OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Moderate to severe psoriasis * Psoriasis affecting the fingernails Exclusion Criteria: * Previous treatment with Enbrel® (etanercept) * Active infection * Rheumatoid arthritis * Any personal or family history of any neurologic demyelinating disease * Receipt of investigational drugs or "biologics" within 4 weeks of the screening visit

What they're measuring

NAPSI

Timeframe: Baseline to 24 weeks

OCT (clinical)

Timeframe: Baseline to 24 weeks

Trial details

NCT IDNCT05135312

SponsorOptiSkin Medical

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-08

Contact for this trial

Moshe Bressler, DO

2128283120 moshe@optiskinmedical.com

View on ClinicalTrials.gov More Psoriasis trials